Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications
In the present study, a nanoapatite-mediated delivery system for imatinib has been proposed. Nanohydroxyapatite (nHAp) was obtained by co-precipitation method, and its physicochemical properties in combination with imatinib (IM) were studied by means of XRPD (X-ray Powder Diffraction), SEM-EDS (Scan...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/25/20/4602 |
| _version_ | 1827704626334400512 |
|---|---|
| author | Paulina Sobierajska Anna Serwotka-Suszczak Damian Szymanski Krzysztof Marycz Rafal J. Wiglusz |
| author_facet | Paulina Sobierajska Anna Serwotka-Suszczak Damian Szymanski Krzysztof Marycz Rafal J. Wiglusz |
| author_sort | Paulina Sobierajska |
| collection | DOAJ |
| description | In the present study, a nanoapatite-mediated delivery system for imatinib has been proposed. Nanohydroxyapatite (nHAp) was obtained by co-precipitation method, and its physicochemical properties in combination with imatinib (IM) were studied by means of XRPD (X-ray Powder Diffraction), SEM-EDS (Scanning Electron Microscopy-Energy Dispersive X-ray Spectroscopy), FT-IR (Fourier-Transform Infrared Spectroscopy), absorption spectroscopy as well as DLS (Dynamic Light Scattering) techniques. The obtained hydroxyapatite was defined as nanosized rod-shaped particles with high crystallinity. The amorphous imatinib was obtained by conversion of its crystalline form. The beneficial effects of amorphous pharmaceutical agents have been manifested in the higher dissolution rate in body fluids improving their bioavailability. Imatinib-to-hydroxyapatite interactions on the surface were confirmed by SEM images as well as absorption and FT-IR spectroscopy. The cytotoxicity of the system was tested on NI-1, L929, and D17 cell lines. The effectiveness of imatinib was not affected by nHAp modification. The calculated IC<sub>50</sub> values for drug-modified nHAp were similar to those for the drug itself. However, higher cytotoxicity was observed at higher concentrations of imatinib, in comparison with the drug alone. |
| first_indexed | 2024-03-10T15:45:54Z |
| format | Article |
| id | doaj.art-8ef6fae95ca6488e898babd62b0f51c2 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T15:45:54Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-8ef6fae95ca6488e898babd62b0f51c22023-11-20T16:29:28ZengMDPI AGMolecules1420-30492020-10-012520460210.3390/molecules25204602Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer ApplicationsPaulina Sobierajska0Anna Serwotka-Suszczak1Damian Szymanski2Krzysztof Marycz3Rafal J. Wiglusz4Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okolna 2, 50-422 Wroclaw, PolandDepartment of Experimental Biology, Wroclaw University of Environmental and Life Sciences, Norwida 27B Street, A7 Building, 50-375 Wroclaw, PolandInstitute of Low Temperature and Structure Research, Polish Academy of Sciences, Okolna 2, 50-422 Wroclaw, PolandDepartment of Experimental Biology, Wroclaw University of Environmental and Life Sciences, Norwida 27B Street, A7 Building, 50-375 Wroclaw, PolandInstitute of Low Temperature and Structure Research, Polish Academy of Sciences, Okolna 2, 50-422 Wroclaw, PolandIn the present study, a nanoapatite-mediated delivery system for imatinib has been proposed. Nanohydroxyapatite (nHAp) was obtained by co-precipitation method, and its physicochemical properties in combination with imatinib (IM) were studied by means of XRPD (X-ray Powder Diffraction), SEM-EDS (Scanning Electron Microscopy-Energy Dispersive X-ray Spectroscopy), FT-IR (Fourier-Transform Infrared Spectroscopy), absorption spectroscopy as well as DLS (Dynamic Light Scattering) techniques. The obtained hydroxyapatite was defined as nanosized rod-shaped particles with high crystallinity. The amorphous imatinib was obtained by conversion of its crystalline form. The beneficial effects of amorphous pharmaceutical agents have been manifested in the higher dissolution rate in body fluids improving their bioavailability. Imatinib-to-hydroxyapatite interactions on the surface were confirmed by SEM images as well as absorption and FT-IR spectroscopy. The cytotoxicity of the system was tested on NI-1, L929, and D17 cell lines. The effectiveness of imatinib was not affected by nHAp modification. The calculated IC<sub>50</sub> values for drug-modified nHAp were similar to those for the drug itself. However, higher cytotoxicity was observed at higher concentrations of imatinib, in comparison with the drug alone.https://www.mdpi.com/1420-3049/25/20/4602nanohydroxyapatiteimatinibanticancer targeted therapiescytotoxicity |
| spellingShingle | Paulina Sobierajska Anna Serwotka-Suszczak Damian Szymanski Krzysztof Marycz Rafal J. Wiglusz Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications Molecules nanohydroxyapatite imatinib anticancer targeted therapies cytotoxicity |
| title | Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications |
| title_full | Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications |
| title_fullStr | Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications |
| title_full_unstemmed | Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications |
| title_short | Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications |
| title_sort | nanohydroxyapatite mediated imatinib delivery for specific anticancer applications |
| topic | nanohydroxyapatite imatinib anticancer targeted therapies cytotoxicity |
| url | https://www.mdpi.com/1420-3049/25/20/4602 |
| work_keys_str_mv | AT paulinasobierajska nanohydroxyapatitemediatedimatinibdeliveryforspecificanticancerapplications AT annaserwotkasuszczak nanohydroxyapatitemediatedimatinibdeliveryforspecificanticancerapplications AT damianszymanski nanohydroxyapatitemediatedimatinibdeliveryforspecificanticancerapplications AT krzysztofmarycz nanohydroxyapatitemediatedimatinibdeliveryforspecificanticancerapplications AT rafaljwiglusz nanohydroxyapatitemediatedimatinibdeliveryforspecificanticancerapplications |